Clinical Trials in Predementia Stages of Alzheimer Disease

Medical Clinics of North America

Volumn 97, Issue 3, 2013, Pages 439-457

  Pillai, Jagan A ^a   Cummings, Jeffrey L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

At risk population; Clinical trial designs; Mild cognitive impairment; Outcome measures; Preclinical Alzheimer's disease; Primary prevention; Prodromal Alzheimer's disease; Secondary prevention

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CRENEZUMAB; DONEPEZIL; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GANTENERUMAB; GROWTH FACTOR; LY 2886721; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PRESENILIN 1; PRESENILIN 2; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APTITUDE TEST; CLINICAL TRIAL (TOPIC); COGNITION; COMPREHENSION; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL NEUROIMAGING; GENE LINKAGE DISEQUILIBRIUM; HUMAN; LANGUAGE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MOLECULAR IMAGING; ORIENTATION; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; RECOGNITION; REVIEW; SECONDARY PREVENTION; SIGNAL NOISE RATIO; STEM CELL;

AGED; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASES; CLINICAL TRIALS AS TOPIC; COGNITION; DRUGS, INVESTIGATIONAL; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PATIENT SELECTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84877064788     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.01.002     Document Type: Review

References (99)

1. Alzheimer's Disease International. World Alzheimer Report 2009. [Accessed on February 06, 2013]. Available at: http://www.alz.co.uk/research/files/World%20Alzheimer%20Report.pdf.
2. Alzheimer's Disease International. World Alzheimer Report 2011.[Accessed on February 06, 2013]. Available at: http://www.alz.co.uk/research/files/World%20Alzheimer%20Report.pdf.
3. Aisen P.S. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging 2011, 32(Suppl 1):S64-S66.
4. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9(11):1118-1127.
5. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6(8):734-746.
6. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270-279.
7. Jack C.R., Albert M.S., Knopman D.S., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):257-262.
8. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):263-269.
9. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):280-292.
10. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111-133.
11. Bennett D.A., Schneider J.A., Arvanitakis Z., et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
12. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69(16):1622-1634.
13. Hendrix S.B. Requiring an amyloid-b1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies. Alzheimers Res Ther 2011, 3(2):10.
14. Mielke M.M., Wiste H.J., Weigand S.D., et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012, 79(15):1570-1577.
15. Acosta-Baena N., Sepulveda-Falla D., Lopera-Gómez C.M., et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 2011, 10(3):213-220.
16. Bateman R., Ringman J.M., Rossor M.N., et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367(9):795-804.
17. Aisen P.S., Ghetti B., Klunk W.E., et al. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988, 43:99-136.
18. Campion D., Dumanchin C., Hannequin D., et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999, 65:664-670.
19. Lleó A., Blesa R., Queralt R., et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 2002, 59(11):1759-1763.
20. Ryan N.S., Rossor M.N. Defining and describing the pre-dementia stages of familial Alzheimer's disease. Alzheimers Res Ther 2011, 3(5):29.
21. Fox N.C., Warrington E.K., Seiffer A.L., et al. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain 1998, 121(Pt 9):1631-1639.
22. Klunk W.E., Price J.C., Mathis C.A., et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007, 27:6174-6184.
23. Ringman J.M., Taylor K., Teng E., et al. Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology 2011, 76:2124-2125.
24. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923.
25. Donix M., Burggren A.C., Suthana N.A., et al. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage 2010, 53(1):37-43.
26. Chen K., Reiman E.M., Alexander G.E., et al. Correlations between apolipoprotein E ε4 gene dose and whole brain atrophy rates. Am J Psychiatry 2007, 164(6):916-921.
27. Burggren A.C., Zeineh M.M., Ekstrom A.D., et al. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 2008, 41(4):1177-1183.
28. Sugarman M.A., Woodard J.L., Nielson K.A., et al. Functional magnetic resonance imaging of semantic memory as a presymptomatic biomarker of Alzheimer's disease risk. Biochim Biophys Acta 2012, 1822(3):442-456.
29. Filippini N., MacIntosh B.J., Hough M.G., et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A 2009, 106(17):7209-7214.
30. Langbaum J.B., Chen K., Lee W., et al. Alzheimer's Disease Neuroimaging Initiative. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009, 45(4):1107-1116.
31. Reiman E.M., Langbaum J.B., Tariot P.N. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010, 4(1):3-14.
32. Cruchaga C., Haller G., Chakraverty S., et al. NIA-LOAD/NCRAD Family Study Consortium. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012, 7(2):e31039.
33. Hinerfeld D.A., Moonis M., Swearer J.M., et al. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol 2007, 64(11):1672-1673.
34. Roses A.D., Lutz M.W., Amrine-Madsen H., et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 2010, 10(5):375-384.
35. Reiman E.M., Langbaum J.B., Fleisher A.S., et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011, 26(Suppl 3):321-329.
36. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65(4):403-413.
37. Jack C.R., Knopman D.S., Jagust W.J., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
38. Delrieu J., Ousset P.J., Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther 2012, 12(8):1077-1086.
39. Schneider L.S., Kennedy R.E., Cutter G.R. Alzheimer's Disease Neuroimaging Initiative. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010, 6(5):367-377.
40. Hendrix S.B. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther 2012, 4(4):24.
41. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
42. Markesbery W.R., Schmitt F.A., Kryscio R.J., et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006, 63:38-46.
43. Mitchell T.W., Mufson E.J., Schneider J.A., et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 2002, 51:182-189.
44. Guillozet A.L., Weintraub S., Mash D.C., et al. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003, 60:729-736.
45. Jicha G.A., Parisi J.E., Dickson D.W., et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006, 63:674-681.
46. Grundman M., Petersen R.C., Ferris S.H., et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004, 61:59-66.
47. Alexopoulos P., Grimmer T., Perneczky R., et al. Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2006, 22:27-34.
48. Visser P.J., Scheltens P., Verhey F.R. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J Neurol Neurosurg Psychiatry 2005, 76(10):1348-1354.
49. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
50. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005, 352:2379-2388.
51. Jelic V., Kivipelto M., Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006, 77:429-438.
52. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
53. Fox N.C., Cousens S., Scahill R., et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease. Neurology 2007, 69:1631.
54. Frisoni G.B., Fox N.C., Jack C.R., et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6(2):67-77.
55. Hansson O., Zetterberg H., Buchhave P., et al. Minthon L Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5(3):228-234.
56. Fagan A.M., Roe C.M., Xiong C., et al. Holtzman DM Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64(3):343-349.
57. Cummings J.L. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging 2000, 21(6):845-861. [review].
58. Murray M.E., Graff-Radford N.R., Ross O.A., et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011, 10(9):785-796.
59. Wilkosz P.A., Seltman H.J., Devlin B., et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 2010, 22(2):281-290.
60. Farlow M.R., Small G.W., Quarg P., et al. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 2005, 20(2-3):192-197.
61. Wallin A.K., Hansson O., Blennow K., et al. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. Int J Geriatr Psychiatry 2009, 24(6):638-647.
62. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997, 336(17):1216-1222.
63. Courtney C., Farrell D., Gray R., et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 2004, 363(9427):2105-2115.
64. Chow S.C., Chang M. Adaptive design methods in clinical trials-a review. Orphanet J Rare Dis 2008, 3:11.
65. Mohs K., Rosen W., Davis K. The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983, 19:448-450.
66. Rosen W., Mohs R., Davis K. A new rating scale for Alzheimer'sdisease. Am J Psychiatry 1984, 141:1356-1364.
67. Cano S.J., Posner H.B., Moline M.L., et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010, 81:1363-1368.
68. Llano D.A., Laforet G., Devanarayan V. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2010, 25:73-84.
69. Harrison J., Minassian S.L., Jenkins L., et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007, 64(9):1323-1329.
70. Gilman S., Koller M., Black R.S., et al. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(9):1553-1562.
71. Perneczky R., Pohl C., Sorg C., et al. Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing 2006, 35(3):240-245.
72. Galasko D.R., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S33-S39.
73. Galasko D., Bennett D.A., Sano M., et al. Alzheimer's Disease Cooperative Study. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord 2006, 20(4 Suppl 3):S152-S169.
74. Gélinas I., Gauthier L., McIntyre M., et al. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther 1999, 53:471-481.
75. Feldman H., Sauter A., Donald A., et al. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001, 15(2):89-95.
76. Mohs R.C., Doody R.S., Morris J.C., et al. A 1-year, placebo controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57:481-488. '312' Study Group.
77. Rockwood K., Fay S., Song X., et al. Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006, 174(8):1099-1105.
78. Leber P. Guidelines for the clinical evaluation of antidementia drugs 1990, Food and Drug Administration, Washington, DC.
79. Rockwood K., Gautheir S. Trial Designs and Outcomes in Dementia Therapeutic Research 2005, Taylor & Francis, Oxon. UK. 1 edition.
80. Cedarbaum J.M., Jaros M., Hernandez C., et al. Alzheimer's Disease Neuroimaging Initiative. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement 2013, 9:S45-S55.
81. Doraiswamy P.M., Sperling R.A., Coleman R.E., et al. AV45-A11 Study Group. Amyloid-b assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
82. Perneczky R., Hartmann J., Grimmer T., et al. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 2007, 20(2):84-88.
83. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S22-S32.
84. Joffres C., Graham J., Rockwood K. Qualitative analysis of the clinician interview based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr 2000, 12(3):403-413.
85. Walsh S.P., Raman R., Jones K.B., et al. Alzheimer's Disease Cooperative Study Group. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord 2006, 20(4 Suppl 3):S170-S178.
86. Fernández-Martínez M., Castro J., Molano A., et al. Prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2008, 5(1):61-69.
87. Lyketsos C.G., Sheppard J.M., Steinberg M., et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001, 16(11):1043-1053.
88. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44(12):2308-2314.
89. Wimo A., Nordberg G., Jansson W., et al. Assessment of informal services to demented people with the RUD instrument. Int J Geriatr Psychiatry 2000, 15(10):969-971.
90. Wimo A., Jonsson L., Zbrozek A. The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging 2010, 14(8):685-690.
91. Wimo A., Gustavsson A., Jönsson L., et al. Application of Resource Utilization in Dementia (RUD) instrument in a global setting. Alzheimers Dement 2012, pii: S1552-5260(12)02387-4. 10.1016/j.jalz.2012.06.008.
92. Wimo A., Nordberg G. Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr 2007, 44(1):71-81.
93. Fillit H., Cummings J., Neumann P., et al. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease. J Nutr Health Aging 2010, 14(8):640-647.
94. Grill J.D., Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010, 2(6):34.
95. Edland S.D., Emond J.A., Aisen P.S., et al. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord 2010, 24:159-164.
96. Thal L.J. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(3 Suppl 2):S97-S99.
97. Bienkowski R.S., Goldfarb N.M. Screen Failures in clinical trials: financial roulette or the cost of doing business?. J Clin Res Best Pract 2008, 4(7):1-4.
98. Knopman D.S., Jack C.R., Wiste H.J., et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78(20):1576-1582.
99. Aisen P.S., Petersen R.C., Donohue M.C., et al. Alzheimer's Disease Neuroimaging Initiative. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010, 6(3):239-246.